Abstract

MGluR2 is G protein-coupled receptor that is targeted for diseases like anxiety, depression, Parkinson’s disease and schizophrenia. Herein, we report the three-dimensional quantitative structure–activity relationship (3D-QSAR) studies of a series of 1,3-dihydrobenzo[ b][1,4]diazepin-2-one derivatives as mGluR2 antagonists. Two series of models using two different activities of the antagonists against rat mGluR2, which has been shown to be very similar to the human mGluR2, (activity I: inhibition of [3H]-LY354740; activity II: mGluR2 (1S,3R)-ACPD inhibition of forskolin stimulated cAMP.) were derived from datasets composed of 137 and 69 molecules respectively. For activity I study, the best predictive model obtained from CoMFA analysis yielded a Q2 of 0.513, R2 ncv of 0.868, R2 pred = 0.876, while the CoMSIA model yielded a Q2 of 0.450, R2 ncv = 0.899, R2 pred = 0.735. For activity II study, CoMFA model yielded statistics of Q2 = 0.5, R2 ncv = 0.715, R2 pred = 0.723. These results prove the high predictability of the models. Furthermore, a combined analysis between the CoMFA, CoMSIA contour maps shows that: (1) Bulky substituents in R7, R3 and position A benefit activity I of the antagonists, but decrease it when projected in R8 and position B; (2) Hydrophilic groups at position A and B increase both antagonistic activity I and II; (3) Electrostatic field plays an essential rule in the variance of activity II. In search for more potent mGluR2 antagonists, two pharmacophore models were developed separately for the two activities. The first model reveals six pharmacophoric features, namely an aromatic center, two hydrophobic centers, an H-donor atom, an H-acceptor atom and an H-donor site. The second model shares all features of the first one and has an additional acceptor site, a positive N and an aromatic center. These models can be used as guidance for the development of new mGluR2 antagonists of high activity and selectivity. This work is the first report on 3D-QSAR modeling of these mGluR2 antagonists. All the conclusions may lead to a better understanding of the mechanism of antagonism and be helpful in the design of new potent mGluR2 antagonists.

Highlights

  • Glutamate is a useful excitatory neurotransmitter of the nervous system, its excessive amount in the brain can lead to cell death through a process called excitotoxicity, which consists of the over stimulation of glutamate receptors

  • Various 3D-Quantitative structure activity relationship (QSAR) models were generated and the best model was selected based on the statistically significant parameters obtained. For both 3D-QSAR studies, good correlations were observed in the obtained comparative molecular field analysis (CoMFA) and comparative molecular similarity analysis (CoMSIA) models demonstrated by the high values of Q2, Rncv, Rpred and other statistical results

  • During the molecular modeling process, 110 compounds out of the total 137 mGluR2 antagonists were used as training set and the remaining 27 compounds were used as test set

Read more

Summary

Introduction

Glutamate is a useful excitatory neurotransmitter of the nervous system, its excessive amount in the brain can lead to cell death through a process called excitotoxicity, which consists of the over stimulation of glutamate receptors. Excitotoxicity occurs in neurological diseases such as Alzheimer’s disease, Parkinson’s disease and multiple sclerosis [1]. G-protein Coupled Receptors linked to multiple second messengers and modulate the ion channel currents [2,3]. Group I receptors include mGluR 1 and 5, group II mGluR2 and 3, and group III mGluR 4, 6, 7 and 8 [4] These mGluRs play essential neuromodulatory roles throughout the brain, as such they are attractive targets for therapeutic intervention for a number of psychiatric and neurological disorders including anxiety, depression, Fragile X, Syndrome, Parkinson’s disease and schizophrenia [5]

Objectives
Methods
Results
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call